NRAS and precursor B-cell acute lymphoblastic leukemia: ASXL1 and NRAS mutations were enriched in patients with 10− 3 ≤ MRD1 < 10− 2 (P = 0.024, P < 0.001, respectively), whereas NRAS and CREBBP mutations were less significantly in B-ALL patients with MRD1 < 10− 3 (P = 0.005, P = 0.042, Fig. 6E).